Najat Khan Recursion Pharmaceuticals, Inc. (RXRX) insider trading activity

Najat Khan is Chief R&D Commercial Officer of RECURSION PHARMACEUTICALS, INC.. Currently has a direct ownership of 668,197 shares of RXRX, which is worth approximately $3.11 Million. The most recent transaction as insider was on Aug 18, 2025, when has been sold 36,599 shares (Class A Common Stock) at a price of $5.52 per share, resulting in proceeds of $202,026. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 668K

5.7% 3M change

34.45% 12M change

Total Value Held $3.11 Million

Najat Khan Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 18 2025	SELL Open market or private sale	$202,026 $5.52 p/Share	36,599 Reduced 5.19%	668,197 Class A Common Stock
Aug 15 2025	SELL Payment of exercise price or tax liability	$21,369 $5.64 p/Share	3,789 Reduced 0.53%	704,796 Class A Common Stock
May 15 2025	SELL Payment of exercise price or tax liability	$16,133 $4.25 p/Share	3,796 Reduced 0.53%	708,585 Class A Common Stock
Feb 03 2025	SELL Payment of exercise price or tax liability	$19,959 $7.25 p/Share	2,753 Reduced 0.38%	712,381 Class A Common Stock
Feb 03 2025	BUY Grant, award, or other acquisition	-	218,162 Added 23.38%	715,134 Class A Common Stock
Aug 01 2024	BUY Grant, award, or other acquisition	-	496,972 Added 50.0%	496,972 Class A Common Stock

Najat Khan

Chief R&D Commercial Officer

Salt Lake City, UT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RXRX shares.

Notify only if

Value

Insider Trading

Get notified when an Recursion Pharmaceuticals, Inc. insider buys or sells RXRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to RECURSION PHARMACEUTICALS, INC.

Track Activities on RXRX

Account